Form 4: Senti Biosciences Executive Sells Shares to Cover Tax Obligations

Kanya Rajangam, Pres. & Chief Med. & Dev. Off. of Senti Biosciences, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Summary

• Kanya Rajangam, the President & Chief Medical & Development Officer of Senti Biosciences, sold shares of common stock on February 4, 2025, and February 6, 2025.
• The sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• On February 4, 2025, 1,297 shares were sold at a price of $4.07 per share.
• On February 6, 2025, 182 shares were sold at a price of $4.37 per share.
• Following these transactions, Rajangam directly owns 8,621 shares of Senti Biosciences common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing relates to routine stock sales for tax purposes and doesn't indicate a change in the executive's overall confidence in the company.

Management Comments

• The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. These filings are closely monitored by investors to gauge management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the slight dilution of shares, but the impact is likely minimal given the purpose of the sales.

Key Dates

Keywords

Senti Biosciences, SNTI, Rajangam, Kanya Rajangam, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units